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Abstract  
 
Within this study, we designed and synthesized four new oxime compounds of the N-substituted 2-
hydroxyiminoacetamide structure and evaluated their interactions with acetylcholinesterase (AChE) 
and butyrylcholinesterase (BChE). Our aim was to explore the possibility of extending the dual-binding 
mode of interaction between the enzyme and the inhibitor to a so-called triple-binding mode of 
interaction through the introduction of an additional binding moiety. N-substituted 2-
hydroxyiminoacetamide 1 was prepared via BOP catalyzed amidation of hydroxyiminoacetic acid with 
3-azido-1-phenylpropylamine. An azide group enabled us to prepare more elaborate structures 2 – 4 by 
the copper-catalyzed azide-alkyne cycloaddition. The new compounds 1 – 4 differed in their presumed 
AChE peripheral site binding moiety, which ranged from an azide group to functionalized heterocycles. 
Molecular docking studies revealed that all three binding moieties are involved in the non-covalent 
interactions with ChEs for all of the four compounds, albeit not always in the complete accordance 
with the proposed hypothesis.  All of the four compounds reversibly inhibited the ChEs with their 
inhibition potency increasing in the same order for both enzymes (1 < 2 < 4 < 3). A higher preference 
for binding to BChE (Ki from 0.30 μmol/L to 130 μmol/L) over AChE (Ki from 50 μmol/L to 1200 
μmol/L) was observed for all of the compounds.  
 
Keywords: Oxime antidotes, Azide-alkyne cycloaddition, Organophosphorus compounds, Inhibition, 
Selectivity  
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1. Introduction 
 
 Acetylcholinesterase (AChE; EC 3.1.1.7) is a key enzyme for the regulation of cholinergic 
transmission in both the central and peripheral nervous system that catalyzes the hydrolysis of the 
neurotransmitter acetylcholine (ACh) [1]. The decline of hippocampal and cortical levels of ACh is a 
characteristic of Alzheimer’s disease (AD), a disabling and fatal neurodegenerative disease manifested 
by memory loss and learning deficits [2]. Thus, today’s drugs designed for the treatment of AD are 
reversible AChE inhibitors that block the enzyme active site leading to an  increase of ACh levels and, 
in turn, to the alleviation of disease symptoms [3]. 
 The active site of AChE is a 20 Å deep gorge divided into two sub-sites; the peripheral anionic 
site (PAS) (Tyr72, Tyr124, Trp286) located at the entrance of the gorge, and the catalytic site (CAS) 
located close to the bottom of the gorge. CAS is composed of the catalytic triad (Ser203, His447, 
Glu334), an oxyanion hole (Gly121, Gly122, Ala204), an acyl-binding pocket (Phe288, Phe290) and a 
choline binding site (Trp86, Tyr337, Phe338) [4,5]. The two sub-sites serve as the recognition sites for 
the ligands that bind to the AChE governing their mechanism of interaction. Depending on the 
established interactions, ligands can be described as PAS-binding or the CAS-binding. Out of several 
anti-AD drugs (Fig. 1), galanthamine (half-maximal inhibitory concentration (IC50) of 2.01 μmol/L in 
human AChE) [6,7] and huperzine A (IC50 of 0.082 μmol/L in mouse AChE) [8,9] bind to the CAS, 
while propidium iodide (IC50 of 1.1 μmol/L in mouse AChE) [10] binds in the PAS region [11]. 
Inhibitors that bind to PAS and CAS simultaneously include both symmetrical (e.g. bistacrine, Kd of 
250 nmol/L in fetal bovine serum AChE) [12,13] and non-symmetrical tacrine analogues (e.g. syn-
TZ2PA6, Kd of 0.41 nmol/L in mouse AChE) [14,15], as well as donepezil (Kd in hAChE of 3.35 
nmol/L (R-donepezil), 17.5 nmol/L (S-donepezil)) an anti-AD drug that binds with a basic nitrogen in 
the CAS and an aromatic system in the PAS [16, 17].
 
Crystal structures of AChE-inhibitor complexes 
have shown that inhibitors usually interact with gorge residues via arene–arene (π-π) interactions. 
Trp86, which is essential for the interaction with the trimethylammonium group of ACh, is considered 
crucial for the stabilization of CAS-binding ligands through cation-π and π-π interactions together with 
the Tyr337, and His447 of the catalytic triad [18-20]. On the other hand, PAS-binding ligands are 
stabilized through π-π interactions with Tyr72, Tyr124, and Trp286 [21-23]. 
 The acute toxicity of organophosphorus (OP) nerve agents (e.g. tabun, soman, sarin, VX) is due 
to their irreversible inhibition of AChE by covalently binding to the catalytic serine residue which 
results in the accumulation of ACh in synaptic clefts [24]. The activity of AChE can be restored by 
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treatment with a reactivator from the quaternary pyridinium oxime family (2-PAM, trimedoxime, 
obidoxime, HI-6, Hlö-7) (Fig. 1) by cleaving the covalent bond between the catalytic serine residue and 
the nerve agent [25,26]. HI-6 (KI for hAChE of 20 μmol/L) [27] is an example of a quaternary bis-
pyridinium oxime that binds to both the CAS and the PAS with its two positively charged heterocyclic 
aromatic rings [28]. The efficacy of both AChE inhibitors and reactivators currently used in medical 
treatment of AD or OP nerve agent poisoning is limited because they do not cross the blood-brain 
barrier readily due to their permanent positive charge [29]. 
 Butyrylcholinesterase (BChE, E.C. 3.1.1.8) is related to AChE and it can also catalyze the 
hydrolysis of ACh; moreover, it serves as a co-regulator of cholinergic neurotransmission [30,31]. 
However, BChE plays an important role in the pathogenesis of AD with its activity increased at the 
early stage of disease and involvement in the amyloid β-peptide aggregation developing into senile 
plaque deposits [32,33]. The inhibition of BChE may thus be beneficial in the medical treatment of AD 
patients. AChE and BChE show a high resemblance with sequence homology of 65 % [33,34]. 
However, their active sites display different amino acids composition and therefore the BChE active 
site is about 200 Å
3 
bigger [35,36], consequently allowing the BChE to bind and hydrolyze larger 
ligands and substrates than AChE [37].
 
Moreover, differences between AChE and BChE active site 
amino acid composition lead to AChE/BChE selectivity for many ligands and substrates [23,38]. Some 
of the selective AChE inhibitors are BW284C51, huperzin A, and the aforementioned donepezil 
[8,17,24,23,]. Several selective BChE inhibitors have also been described, including bambuterol and 
ethopropazine (Fig. 1) [39-43]. Using ChE active site differences for designing selective inhibitors 
could help develop improved AD drugs and reactivators of OP nerve agent-inhibited enzymes. 
 In this study, we designed and synthesized four new compounds to probe the possibility of 
simultaneous non-covalent triple-binding between the inhibitors and the ChE. Our results could lead to 
the discovery of more selective ChE inhibitors as well as more effective reactivators of OP nerve agent-
inhibited enzymes. Compounds were designed by modifying the structures of N-substituted 2-
hydroxyiminoacetamides, recently introduced non-charged AChE oxime reactivators [44,45], through 
the introduction of a phenyl ring. It was expected that the phenyl ring would help their stabilization 
through π-π interactions with active site aromatic amino acids and provide additional binding moiety 
apart from PAS- moiety and the 2-hidroxyiminoacetamide group. The working hypothesis was that the 
phenyl ring would interact with the choline binding site directing, together with PAS-binding moiety, 
the 2-hidroxyiminoacetamide group into a so-called third binding site surrounding Ser203. Molecular 
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modelling was used to determine and visualize the binding modes of the new compounds and their 
interactions with the enzymes. 
 
2. Materials and methods 
2.1. Chemicals 
N-substituted 2-hydroxyiminoacetamides N-(3-azido-1-phenylpropyl)-2-hydroxyiminoacetamide (1), 
N-(3-(4-cyclopentyl-1H-1,2,3-triazol-1-yl)-1-phenylpropyl)-2-hydroxyiminoacetamide (2), 2-hydroxy-
imino-N-(3-(4-((2-methyl-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-phenylpropyl)acetamide 
(3), and 2-hydroxyimino-N-(3-(4-((2-hydroxyiminomethyl)-1H-imidazol-1-yl)methyl)-1H-1,2,3-
triazol-1-yl)-1-phenylpropyl)acetamide (4) were synthesized. 1 was prepared via BOP catalyzed 
amidation of hydroxyiminoacetic acid with 3-azido-1-phenylpropylamine [46]. 2–4 were prepared by 
copper catalyzed azide-alkyne cycloaddition starting from 1 and a corresponding alkyne: 
ethynylcyclopentane, 2-methyl-1-(prop-2-yn-1-yl)-1H-imidazole, and 1-(prop-2-yn-1-yl)-1H-
imidazole-2-carbaldehyde oxime, respectively [47,48]. For more detailed information about the 
synthesis of 1–4, please refer to the Supplementary material. 
    
2.2. In vitro enzyme inhibition studies 
 Reversible inhibition of AChE/BChE by N-substituted 2-hydroxyiminoacetamides was 
evaluated by determining the decrease of enzyme activity in the presence of N-substituted 2-
hydroxyiminoacetamides and substrate acetylthiocholine (ATCh). Enzyme activity was measured 
spectrophotometrically using the Ellman assay with 5,5´-dithiobis(2-nitrobenzoic acid) (DTNB) and 
substrate acetylthiocholine (ATCh, 0.1-0.3 mmol/L) [49]. Horse serum BChE was purchased from 
Sigma Chemical Co., USA. Final BChE dilution was 600 fold. Human recombinant AChE was 
prepared at the Jean-Pierre Ebel Institute of Structural Biology (IBS)–DYNAMOP, Grenoble, Rhône-
Alpes, France and was a gift from Dr. Florian Nachon. ATCh and DTNB were purchased from Sigma 
Chemical Co., USA. N-substituted 2-hydroxyiminoacetamides were dissolved in DMSO. ATCh and 
DTNB were dissolved in 0.1 mol/L sodium phosphate buffer (pH 7.4). The reaction mixture contained 
the enzyme suspended in 0.1 mol/L sodium phosphate buffer (pH 7.4), 0.3 mmol/L DTNB, N-
substituted 2-hydroxyiminoacetamide and ATCh (0.1 – 0.8 mmol/L). The final assay volume was 300 
μL and the enzymatic reaction was followed during 240 seconds at a temperature of 25 ºC using a 
Tecan Infinite M200PRO plate reader (Tecan Group Ltd., Switzerland). To limit the influence of 
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DMSO on the degree of enzyme inhibition, the final content of DMSO was held constant whenever it 
exceeded 0.05 %. 
The inhibition constants were evaluated by the Enzyme Kinetics module of Graph Pad Prism 
version 6.01 (GraphPad Software, Inc., USA). The dose response curves were fitted using the Mixed 
Model Inhibition equation: 
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where S is the concentration of substrate ATCh, I is the concentration of inhibitor (oxime), KI is the 
enzyme–oxime inhibition (dissociation) constant of a complex formed at the catalytic site, αKI is the 
Michaelis complex–oxime inhibition (dissociation) constant of a complex formed at the peripheral site, 
Km is a dissociation constant of the Michaelis complex, and Vm is maximal activity. 
 
2.3. Molecular modelling 
 Compounds to be docked in the active site of human AChE and human BChE were created and 
minimized using the MMFF94 force field implemented in ChemBio3D Ultra 12.0 (PerkinElmer, Inc., 
USA).  
 Accelrys Discovery Studio’s Dock Ligands protocol (CDOCKER) was used for the docking 
study with CHARMm force field (Accelrys, USA) [50,51]. The crystal structure of human AChE 
(PDB: 1B41, 4PQE) [52] or human BChE (PDB: 2PM8) [53] was used as the rigid receptor. The 
binding site within the AChE or BChE was defined as the largest cavity in the enzyme structure 
surrounded by a sphere (r = 13 Å). The following steps were included in the CDOCKER protocol. 
First, a set of 20 random ligand conformations for each test compound was generated. In the following 
step, 20 random orientations were kept if the energy was less than the specified threshold value of 300 
vdW. This process continued until either a desired number of low-energy orientations were found or 
the maximum number of bad orientations had been attempted. The maximum number of bad 
orientations was set to 800. In the next step each orientation was subjected to simulated annealing 
molecular dynamics. The temperature was increased to 700 K then cooled to 310 K. The numbers of 
heating and cooling phase steps during simulated annealing were set to 2000 and 5000, respectively. 
For the simulated annealing refinement, grid extension (8.0 Å) was used. In the subsequent step, a final 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
6 
 
minimization of each refined pose of the ligand in the rigid receptor is performed using full potential. 
In the end, for each final pose, the CHARMm energy (interaction energy plus ligand strain) and the 
interaction energy alone are calculated. The poses are sorted by CHARMm energy and the 20 top 
scored (most negative, thus favorable for binding) poses are retained. 
The selected poses for each enzyme–ligand complex were minimized using protocol 
Minimization with Smart Minimizer algorithm. The applied algorithm performs 1000 steps of Steepest 
Decent with a RMS gradient tolerance of 3, followed by Conjugate Gradient minimization with the 
values of Max Steps and RMS Gradient set to 500 and 0.01, respectively. Generalized Born with 
Molecular Volume implicit solvent model was used [54,55]. The non-polar surface area was used to 
approximate the non-polar component of the solvation energy. Implicit solvent dielectric constant was 
set to 80. Distance cutoff value used for counting non-bonded interaction pairs was set to 14.0 Å.    
 
3. Results and discussion 
3.1. Kinetic measurements 
 Based on the hypothesis that the dual-binding mode of interaction between AChE/BChE and its 
inhibitors or reactivators can be extended to a so-called triple-binding mode of interaction, we designed 
and synthesized four new compounds capable of simultaneous non-covalent triple-binding with 
enzymes. In doing so, we modified the structures of recently reported N-substituted 2-
hidroxyimnoacetamides [44] by introducing the phenyl ring. Some of the reported N-substituted 2-
hidroxyiminoacetamides are known to possess high reactivation potential toward sarin-, cyclosarin-, 
and VX-inhibited AChE [45]. According to our hypothesis, the phenyl ring was expected to bind in the 
choline binding site. The presumed PAS-binding moieties ranged from an azide group to functionalized 
heterocycles and were connected with the central N-(1-phenylpropyl)-2-hydroxyiminoacetamide 
scaffold via a 1,2,3-triazole ring. Following N-substituted 2-hydroxyiminoacetamides were 
synthesized: N-(3-azido-1-phenylpropyl)-2-hydroxyiminoacetamide (1), N-(3-(4-cyclopentyl-1H-1,2,3-
triazol-1-yl)-1-phenylpropyl)-2-hydroxyiminoacetamide (2), 2-hydroxyimino-N-(3-(4-((2-methyl-1H-
imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-phenylpropyl)acetamide (3), and 2-hydroxyimino-N-(3-
(4-((2- hydroxyiminomethyl)-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-phenylpropyl)acet-
amide (4) (Fig. 2). 
 To determine the binding affinity of AChE and BChE for 1–4, we performed detailed enzyme 
kinetics measurements (Fig. 3). All four of the N-substituted 2-hydroxyiminoacetamides reversibly 
inhibited both AChE and BChE displaying mixed types of inhibition. This suggests that all four oximes 
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can bind to the free enzyme (E) and to the Michaelis complex (ES). Parameter α > 1 describes the 
decrease in the ES complex affinity for an oxime in comparison to the affinity of the free enzyme (E). 
All of the tested oximes bind more weakly to the ES than to the E in the case of AChE, except for 2. 
However, due to the low solubility of 2 in 0.1 M sodium phosphate buffer, its kinetic parameters could 
not be evaluated at the optimal concentration range which may explain its exceptional behavior. For 
BChE, this decrease in ES affinity is even more pronounced indicating obstruction of interactions 
between the oxime and gorge residues due to the substrate presence. Inhibition constants (Ki) for AChE 
ranged from 50 to 1200 μmol/L (Table 1) with the inhibition potency increasing in the following order: 
1 < 2 < 4 < 3. For BChE, Ki ranged from 0.3 to 130 μmol/L with the same order of inhibition potency 
as the one observed for AChE. Results show that our modification of the presumed PAS-binding 
moieties can influence inhibition potency significantly. Compound 1 displayed the lowest affinity 
toward the enzymes, which is probably the result of the lack of a more elaborated structure of its 
presumed PAS-binding moiety, i.e. an azide group present in 2, 3 and 4. On the other hand, 3 proved to 
be the most potent inhibitor of both enzymes. Also, all four oximes demonstrated a preference for 
binding to BChE, probably due to a bigger BChE active site compared to AChE allowing such bulkier 
ligands to adopt more favorable binding conformation [37]. Also, 6 out of 14 aromatic amino acids in 
the AChE active site corresponding to aliphatic ones in the BChE site made it more hydrophobic and 
favorable for lipophilic compounds. Moreover, 3 displayed an almost 150 times higher affinity for 
BChE compared to AChE, thus 3 can be considered a selective BChE inhibitor. 
 
3.2. Molecular modeling 
In order to reveal the key interactions leading to the observed differences in binding affinity of 1–4 and 
their preference for binding to BChE, molecular docking studies were conducted using structures of 
human AChE (PDB: 1B41, 4PQE) and human BChE (PDB: 2PM8) (Fig. 4 and 5). 1–4 were docked 
into the active site of the enzyme. The resulting poses were critically investigated targeting the ones 
including π-π interactions between a compound and aromatic amino acids of PAS and choline binding 
sites – a type of interaction typical of enzyme-inhibitor/reactivator complex observed by X-ray 
crystallography for both AChE and BChE [12,18-23,28,56,57]. Poses that had fulfilled these criteria 
were chosen for the prediction of key interactions between the compound and the enzyme summarized 
in Table 2. In agreement with experimentally determined enzyme–N-substituted 2-
hydroxyiminoacetamide inhibition constants, 3 displayed the highest number of predicted interactions 
with both enzymes, while the weakest inhibitor 1 displayed the lowest number of interactions. On the 
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other, it was clear that the differences in inhibition potencies and their preference for binding to BChE 
could not be attributed solely to the number of interactions with the enzyme. 
 
3.2.1. Modeling of AChE complexes 
 The predicted binding geometry of 1 in the AChE active site supported our hypothesis that a 
phenyl ring would bind in the choline binding site yielding π-π interactions with Trp86 (Fig. 4A). As 
mentioned, this type of interaction has been confirmed from structures for numerous complexes of 
ChEs and aromatic ring-containing ligands, i.e. parallel π–π stacking between the benzyl ring of the 
donepezil complexed with human (h) AChE Trp86 or Torpedo californica (Tc) AChE Trp84 [17,58], 
π–π stacking of the tacrine ring against the Trp84 in the tacrine–TcAChE complex [59] and bistacrine–
TcAChE complex [13], and against the Trp82 in the tacrine–hBChE complex [56]. Also in accordance 
with our hypothesis, the 2-hydroxyiminoacetamide moiety was directed toward the catalytic serine 
Ser203 making hydrogen bonds between its hydroxyl group and Ser203 and/or His447 of the catalytic 
triad. Additionally, a side chain of 1 with an azide group makes hydrogen bonds with Tyr133. This 
residue makes hydrogen bonds with ligands, i.e. (–)-huperzine A in complex with hAChE [56]. The 
lack of interactions between 1 and the residues in the PAS region could explain its low inhibition 
potential when compared to other N-substituted 2-hydroxyiminoacetamides. 
Model complex of 2 and AChE (Fig. 4B) also predicts π-π interactions between the phenyl ring 
and Trp86. The triazole ring, absent in 1, makes hydrogen bonds with Tyr124 which is similar to a 
hydrogen bond between the phenol ring of Tyr124 and the pyridinium ring of the 2-hydroxy-
iminomethylpyridinium ring of HI-6 in complex with mAChE [60]. These interactions seem to govern 
the overall binding mode of 2 in the AChE active site directing the presumed PAS-binding moiety, i.e. 
the cyclopentyl ring, in the PAS and the 2-hydroxyiminoacetamide moiety toward the catalytic serine 
with which it makes hydrogen bonds via its oxime group [57]. 
Elongated binding conformation of 3 in the AChE active site (Fig. 4C) is characterized with a 
methylimidazole ring, directed towards the entry of the AChE gorge and the 2-hydroxyiminoacetamide 
moiety directed towards the bottom of the gorge. The geometry of 3 in the AChE gorge leads to 
multiple π-π interactions with aromatic amino acids; the imidazole ring with Trp286, the triazole ring 
with Tyr341 and with Phe297 (π-sigma interaction), and the phenyl ring interacts with Tyr124.  This is 
in accordance with X-ray structures of oximes HI-6, Ortho-7, and obidoxime in complex with mAChE 
[58], and donepezil in complex with TcAChE [17]. Additionally, the 2-hydroxyiminoacetamide moiety 
of 3 creates a hydrogen bond with Glu202. 
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The predicted binding geometry of 4 in the AChE (Fig. 4D) suggests that 4 also binds with its 
presumed PAS-binding moiety, imidazole-2-carboxaldehyde oxime, at the entry of the gorge and the 
phenyl ring at the choline binding site. The triazole ring binds in the narrow part defined by Tyr124 and 
Tyr337. The only difference between the predicted binding geometry of 3 and 4 was that 4 had been 
buried deeper in the AChE active site. This results in π-π interactions between the imidazole-2-
carboxaldehyde oxime and Trp341. Additionally, 2-hydroxyiminoacetamide group makes hydrogen 
bonds with Glu202 and Ser203.
 
However, this also leads to the loss of interaction between the 
imidazole ring and PAS residues Tyr124 and Trp286 which could explain the lower inhibition potential 
of 4 when compared to 3. 
 
3.2.2. Modeling of BChE complexes 
 The most commonly observed change in the predicted binding geometry of 1–4 in the BChE 
active site when compared to those for AChE has to do with the energetically more favorable bended 
conformations of oximes in the BChE active site, a finding which reflects the larger BChE active site 
volume. The complex of 1 in the BChE active site (Fig. 5A) again supports our hypothesis that a 
phenyl ring would bind in the choline binding site making π-π interactions with Trp82. However, in the 
BChE active site the phenyl ring is placed closer to the center of the choline binding site. This change 
in the positioning of the phenyl ring is made possible because bulky Tyr337 in the AChE corresponds 
to smaller Ala328 in the BChE. Additionally, the side chain modified with an azide group is oriented 
almost parallel to the Trp82 main chain making π–π interactions with its indole ring and the 2-
hydroxyiminoacetamide moiety is directed towards Ser203 making multiple hydrogen bonds. Once 
again, the lack of interactions between 1 and the residues in the PAS region could explain its lowest 
inhibition potential among all of the tested compounds. 
The complex of 2 and BChE (Fig. 5B) predicts binding for 2 almost perpendicularly to the axis 
connecting the entry and the bottom of the active site gorge. This orientation is made possible because 
aromatic Tyr124, Phe297, and Tyr337 in the AChE active site correspond to smaller Gln119, Val288, 
and Ala328 in the BChE active site, respectively. Otherwise, these aromatic amino acids in the AChE 
active site would not allow such an orientation of 2. Thereby, the cyclopentyl ring occupies the space 
normally inaccessible in the AChE active site. 2-hydroxyiminoacetamide moiety is directed towards 
the acyl pocket with its hydroxyl group and making hydrogen bonds with Leu286. Additionally, the 
carbonyl oxygen of the 2-hydroxyiminoacetamide moiety makes hydrogen bonds with Ser198. 
Contrary to our hypothesis, the phenyl ring is shifted towards the entry of the BChE active site gorge, 
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but is just close enough to Phe329 to make a π-π interaction. This distinct residue corresponds to 
Phe338 in the AChE active site which participates in aromatic interactions, the donepezil complex with 
TcAChE [17] and the HI-6 complex with mAChE [60]. 
Model complex of 3 and BChE (Fig. 5C) predicts geometry where 3 is in a bended 
conformation and is placed in the center of the BChE active site. Once again this is expected due to 
Gln119, Val288, and Ala328. Thereby, the methylimidazole ring occupies the volume otherwise 
restricted in the AChE active site because of the Tyr337 side chain and interacts with Trp82 and 
His438 via π-π interactions. The 2-hydroxyiminoacetamide moiety is directed towards the bottom of 
the active site where its amide hydrogen makes hydrogen bonds with the backbone of Pro285 and the 
oxime group makes hydrogen bonds with Gly116 and Gly117 from an oxyanion hole, as well as with 
Ser198. It has been assumed that hydrogen bonding with Pro285 has been partially responsible for the 
inhibition differences of horse, human, and mouse BChE [41]. 
The complex of 4 and BChE (Fig. 5D) shows that the imidazole-2-carboxaldehyde oxime and 
the following triazole ring are located in the upper part of the active site while the phenyl ring and the 
2-hydroxyiminoacetamide moiety are located close to the bottom of the active site. Such positioning of 
the triazole ring allows it to make π-π interactions with Tyr332 that corresponds to Tyr341 in the AChE 
site. In support of our hypothesis, the phenyl ring was placed at the bottom of the BChE active site 
close enough to yield a π-π interaction with Trp82. This distinct tryptophan residue is also involved in 
π-sigma interaction with a hydrogen atom from one of the 4 methylene groups and Trp82 main chain 
makes a hydrogen bond with the hydroxyl group of the 2-hydroxyiminoacetamide moiety. The former 
interaction could be related to that between the methylene group in the tetrahydroazepine ring of (–)-
galanthamine in complex with TcAChE [57]. The 2-hydroxyiminoacetamide moiety is located close to 
the center of the BChE active site and is almost perpendicular to the axis connecting the entry and the 
bottom of the active site gorge. Also, it is directed into the area between the Trp82 main chain and 
Thr120 side chain with which it makes another hydrogen bond via its carbonyl oxygen. 
 
4. Conclusion 
 All four compounds reversibly inhibited BChE with inhibition constants ranging from 0.30 
μmol/L to 130 μmol/L. The inhibition potency of compounds increased in the following order: 1 < 2 < 
4 < 3. AChE was also reversibly inhibited by all compounds with the same order of inhibition potency. 
Inhibition constants ranged from 50 μmol/L to 1200 μmol/L. All of the compounds displayed a higher 
preference for binding to BChE.  
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It can be concluded from molecular docking studies that the predicted binding modes of 2–4 in 
the AChE active site support our hypothesis of a so-called triple-binding mode of interaction with the 
enzyme, with the presumed PAS-binding moiety in the PAS, the phenyl ring in the choline binding site, 
and the 2-hydroxyiminoacetamide moiety in the third binding site surrounding active serine. On the 
other hand, none of the N-substituted 2-hydroxyiminoacetamides is predicted to bind in the BChE 
active site in complete accordance with the above stated hypothesis, though all three binding groups are 
involved in non-covalent interactions with the enzyme. However, most of the predicted interactions 
between N-substituted 2-hydroxyiminoacetamides and ChEs could be supported with interactions 
observed from the X-ray structures of various ligands complexed with ChE. To the best of our 
knowledge, only a few interactions in the BChE active site, namely π-π interactions between His438 
and the methylimidazole ring of 3, hydrogen bond between Phe295 and the 2-hydroxyiminoacetamide 
moiety of 3, hydrogen bond between Trp82 and the 2-hydroxyiminoacetamide moiety of 4, and the 
hydrogen bond between Thr120 and the 2-hydroxyiminoacetamide moiety of 4 could not have been 
supported with interactions revealed by X-ray crystallography. The differences in the predicted binding 
modes of 1–4 between the two enzymes reflect different stereoelectronic properties of their active sites 
caused because 6 out of 14 aromatic amino acids in the AChE active site corresponded to aliphatic ones 
in the BChE active site. The most important ones that primarily governed the differences in the 
predicted binding modes of 1–4 occured at the position of Tyr72, Tyr124, Phe297 and Tyr337 in the 
AChE active site. 
 Knowledge of the degree of AChE/BChE selectivity of oxime compounds is may be important 
for more successful treatment in cases of OP nerve agent poisoning. The most notable pretreatment 
strategies include protection of the AChE catalytic serine from phosphylating agent by ligands that bind 
reversibly to AChE [61-65] and the use of bioscavengers, i.e. BChE, prone to inhibition by a 
phosphylating agent [66,67]. Furthermore, BChE is considered to act as a natural bioscavenger in the 
bloodstream [68,69]. Considering the especially high degree of preference for binding to BChE 
displayed by N-substituted 2-hydroxyiminoacetamide 3, our results clearly discourage its use in the 
protection of the AChE catalytic site from a phosphylating agent by reversible inhibition of AChE. 
Moreover, it would also diminish the BChE endogenous bioscavenging capability by inhibiting BChE 
if administered prior to the OP nerve agent exposure. However, if its preference for binding to BChE 
proved to be retained in the case of a phosphylated enzyme and was followed by a fast reactivation, 
together with BChE it could make an enzyme-oxime pair acting as a pseudo catalytic-scavenger [70]. 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
12 
 
Conflict of Interest 
The authors declare that there are no conflicts of interest associated with this work. 
 
Acknowledgements 
The authors thank Dr. Florian Nachon for recombinant human AChE. This study was supported by the 
Croatian Science Foundation (Grant 4307).  
 
References 
[1] J.L. Taylor, R.T. Mayer, C.M. Himel, Conformers of acetylcholinesterase - a mechanism of 
allosteric control, Mol. Pharm. 45 (1994) 74−83. 
[2] E.K. Perry, B.E. Tomlinson, G. Blessed, K. Bergmann, P.H. Gibson, R.H. Perry, Correlation of 
cholinergic abnormalities with senile plaques and mental test scores in senile dementia, Br. Med. J. 2 
(1978) 1457−1459. 
[3] A. Enz, R. Amstutz, H. Boddeke, G. Gmelin, J. Malonowski, Brain selective inhibition of 
acetylcholinesterase: a novel approach to therapy for Alzheimer's disease, Prog. Brain Res. 98 (1993) 
431−435.  
[4] P. Taylor, Z. Radić, The cholinesterases: from genes to proteins, Annu. Rev. Pharmacol. Toxicol. 
34 (1994) 281−320. 
[5] A. Ordentlich, D. Barak, C. Kronman, Y. Flashner, M. Leitner, Y. Segall, N. Ariel, S. Cohen, B. 
Velan, A. Shafferman, Dissection of the human acetylcholinesterase active centre determinants of 
substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and 
the acyl pocket, J Biol Chem 268 (1993) 17083−17095. 
[6] M.F. Eskander, N.G. Nagykery, E.Y. Leung, B. Khelghati, C. Geula, Rivastigmine is a potent 
inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles, Brain Res. 1060 
(2005) 144−152. 
[7] C. Galdeano, E. Viayna, P. Arroyo, A. Bidon-Chanal, J.R. Blas, D. Munoz-Torrero, F.J. Luque, 
Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase 
inhibitors as anti-Alzheimer agents, Curr. Pharm. Des. 16 (2010) 2818−2836. 
[8] R.W. Zhang, X.C. Tang, Y.Y. Han, G.W. Sang, Y.D. Zhang, Y.X. Ma, C.L. Zhang, R.M. Yang, 
Drug-evaluation of huperzine-a in the treatment of senile memory disorders, Acta Pharm. Sin. 12 
(1991) 250−252. 
[9] R. Wang, H. Yan, X.C. Tang, Progress in studies of huperzine A, a natural cholinesterase inhibitor 
from Chinese herbal medicine, Acta Pharmacol. Sin. 27 (2006) 1−26. 
[10] Z. Radić, P. Taylor, Interaction kinetics of reversible inhibitors and substrates with 
acetylcholinesterase and its fasciculin 2 complex, J. Biol. Chem. 276 (2001) 4622−4633. 
[11] Y. Bourne, P. Taylor, Z. Radić, P. Marchot, Structural insights into ligand interactions at the 
acetylcholinesterase peripheral anionic site, Embo J. 22 (2003) 1−12. 
[12] P.R. Carlier, Y.F. Han, E.S.H. Chow, C.P.L. Li, H. Wang, T.X. Lieu, H.S. Wong, Y.P. Pang, 
Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis, 
Bioorg. Med. Chem. 7 (1999) 351−357. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
13 
 
[13] E.H. Rydberg, B. Brumshtein, H.M. Greenblatt, D.M. Wong, D.Shaya, L.D. Williams, P.R. 
Carlier, Y.P. Pang, I. Silman, J.L. Sussman, Complexes of alkylene-linked tacrine dimers with Torpedo 
californica acetylcholinesterase: binding of bis(5)-tacrine produces a dramatic rearrangement in the 
active-site gorge, J. Med. Chem. 49 (2006) 5491−5500. 
[14] W.G. Lewis, L.G. Green, F. Grynszpan, Z. Radić, P.R. Carlier, P.Taylor, M.G. Finn, K.B. 
Sharpless, Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly 
of a femtomolar inhibitor from an array of building blocks, Angew. Chem. Int. Ed. 41 (2002) 
1053−1057. 
[15] Y. Bourne, H.C. Kolb, Z. Radić, K.B. Sharpless, P. Taylor, P. Marchot, Freeze-frame inhibitor 
captures acetylcholinesterase in a unique conformation, P. Natl. Acad. Sci. USA 101 (2004) 
1449−1454. 
[16] A. Inoue, T. Kawai, M. Wakita, Y. Imura, H. Sugimoto, Y. Kawakami, The simulated binding of 
(+/–)-2,3-dihydro-5,6-dimethoxy-2-[(1-(phenylmethyl)-4-piperidinyl)methyl]-1H-inden-1-one 
hydrochloride (E2020) and related inhibitors to free and acylated acetylcholinesterases and 
corresponding structure-activity analyses, J. Med. Chem. 39 (1996) 4460−4470. 
[17] G. Kryger, I. Silman, J.L. Sussman, Structure of acetylcholinesterase complexed with E2020 
(Aricept (R)): implications for the design of new anti-Alzheimer drugs, Structure 7 (1999) 297−307. 
[18] D.A. Dougherty, D.A. Stauffer, Acetylcholine binding by a synthetic receptor: implications for 
biological recognition, Science 250 (1990) 1558−1560. 
[19] D.A. Dougherty, Cation-pi interactions in chemistry and biology: a new view of benzene, Phe, 
Tyr, and Trp, Science 271 (1996) 163−168. 
[20] I. Silman, M. Harel, J. Eichler, J.L. Sussman, A. Anselmet, J. Massoulié, Structure-Function 
Relationships in The Binding of Reversible Inhibitors in the Active-Site Gorge of Acetylcholinesterase, 
in: R. Becker, E. Giacobini (Eds.), Alzheimer Disease: Therepeutic Strategies. Birkäuser, Boston, 
1994, pp. 88−92. 
[21] Z. Radić, R. Durán, D.C. Vellom, Y. Li, C. Cerveñansky, P. Taylor, Site of fasciculin interaction 
with acetylcholinesterase, J. Biol. Chem. 269 (1994) 11233−11239.  
[22] Y. Bourne, P. Taylor, P. Marchot, Acetylcholinesterase inhibition by fasciculin:  crystal structure 
of the complex. Cell 83 (1995) 503−512. 
[23] Z. Radić, N.A. Pickering, D.C. Vellom, S. Camp, P. Taylor, Three distinct domains in the 
cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors, 
Biochemistry 32 (1993) 12074−12084. 
[24] S.M. Somani, J.A. Romano Jr., Chemical Warfare Agents: Toxicity at Low Levels. CRC Press 
LLC, Boca Raton, Florida 2001. 
[25] M.P. Stojiljković, M. Jokanović, Pyridinium oximes: Rationale for their selection as causal 
antidotes against organophosphate poisonings and current solutions for auto-injectors, Arh. Hig. Rada 
Toksikol. 57 (2006) 435–443.  
[26] F. Worek, P. Eyer, N. Aurbek, L. Szinicz, H. Thiermann, Recent advances in evaluation of oxime 
efficacy in nerve agent poisoning by in vitro analysis, Toxicol. Appl. Pharmacol. 219 (2007) 226–234. 
[27] G. Šinko, J. Brglez, Z. Kovarik, Interactions of pyridinium oximes with acetylcholinesterase, 
Chem. Biol. Interact. 187 (2010) 172–176. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
14 
 
[28] F. Ekström, A. Hörnberg, E. Artursson, L.G. Hammarström, G. Schneider, Y.P. Pang, Structure of 
HI-6-sarin-acetylcholinesterase determined by X-ray crystallography and molecular dynamics 
simulation: Reactivator mechanism and design, PLoS One 4 (2009) e5957, 
doi:10.1371/journal.pone.0005957. 
[29] P. Taylor, Anticholinesterase agents, in:  L.L. Brunton, B.A. Chabner, B.C. Knollman (Eds.), 
Goodman and Gilman’s the Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 2011, 
pp. 239–254. 
[30] V. Kumar, Introduction to cholinesterase inhibitors used in Alzheimer's disease therapy, in: R. 
Becker, E. Giacobini (Eds.), Alzheimer Disease: Therepeutic Strategies. Birkäuser, Boston, 1994, pp. 
99–102. 
[31] M.M. Mesulam, A. Guillozet, P. Shaw, A. Levey, E.G. Duysen, O. Lockridge, 
Acetylcholinesterase knockouts establish central cholinergic pathways and can use 
butyrylcholinesterase to hydrolyze acetylcholine, Neuroscience 110 (2002) 627–639. 
[32] S. Darvesh, D.A. Hopkins, C. Geula, Nat. Neurobiology of butyrylcholinesterase. Neurosci. 4 
(2003) 131–138. 
[33] V.N. Talesa, Acetylcholinesterase in Alzheimer's disease, Mech. Ageing Dev. 122 (2001) 1961–
1969. 
[34] Y. Nicolet, O. Lockridge, P. Masson, J.C. Fontecilla-Camps, F. Nachon, Crystal structure of 
human butyrylcholinesterase and of its complexes with substrate and products, J. Biol. Chem. 278 
(2003) 41141−41147. 
[35] H. Dvir, I. Silman, M. Harel, T.L. Rosenberry, J.L. Sussman, Acetylcholinesterase: From 3D 
Structure to Function. Chem. Biol. Interact. 187 (2010) 10−22. 
[36] N.A. Çokuğras, Butyrylcholinesterase: structure and physiological importance. Turk. J. Biochem. 
28 (2003) 54−61. 
[37] A. Saxena, A.M.G. Redman, X. Jiang, O. Lockridge, B.P Doctor, Differences in active-site gorge 
dimensions of cholinesterase revealed by binding of inhibitors to human butyrylcholinesterase, Chem. 
Biol. Interact 119−120 (1999) 61−69. 
[38] P. Taylor, Z. Radić, N.A. Hosea, S. Camp, P. Marchot, H.A. Berman, Structural bases for the 
specificity of cholinesterase catalysis and inhibition, Toxicol. Lett. 82−83 (1995) 453−458. 
[39] Z. Kovarik, Z. Radić, B. Grgas, M. Škrinjarić-Špoljar, E. Reiner, V. Simeon-Rudolf, V,  
Amino acid residues involved in the interaction of acetylcholinesterase and butyrylcholinesterase with 
the carbamates Ro 02-0683 and bambuterol, and with terbutaline, Biochim. et Biophys. Acta 1433 
(1999) 261−271. 
[40] Z. Kovarik, V. Simeon-Rudolf,  Interaction of human butyrylcholinesterase variants with 
bambuterol and terbutaline, J. Enzym. Inhib. Med. Chem. 19 (2004) 113−117. 
[41] Z. Kovarik, A. Bosak, G. Šinko, T. Latas, Exploring active sites of cholinesterases by inhibition 
with bambuterol and haloxon. Croat. Chem. Acta 76 (2003) 63−67. 
[42] M. Goličnik, G. Šinko, V. Simeon-Rudolf, Z. Grubič, J. Stojan, Kinetic model of ethopropazine 
interaction with horse serum butyrylcholinesterase and its docking into the active site, Arch. Biochem. 
Biophys. 398 (2002) 23−31. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
15 
 
[43] G. Šinko, Z. Kovarik, E. Reiner, V. Simeon-Rudolf, J. Stojan, Mechanism of stereoselective 
interaction between butyrylcholinesterase and ethopropazine enantiomers, Biochimie 93 (2011) 
1797−1807. 
[44] R.K. Sit, Z. Radić, V. Gerardi, L. Zhang, E. Garcia, M. Katalinić, G. Amitai, Z. Kovarik, V.V. 
Fokin, K.B. Sharpless, P. Taylor, New structural scaffolds for centrally acting oxime reactivators of 
phosphylated cholinesterases, J. Biol. Chem. 286 (2011) 19422–19430. 
[45] Z. Kovarik, N. Maček, R.K. Sit, Z. Radić, V.V. Fokin, K.B. Sharpless, P. Taylor, Centrally acting 
oximes in reactivation of tabun-phosphoramidated AChE, Chem. Biol. Interact. 203 (2013) 77–80. 
[46] A. Knežević, V. Vinković, N. Maraković, G. Šinko, Enzyme-catalysed cascade synthesis of 
hydroxyiminoacetamides, Tetrahedron Lett. 55 (2014) 4338–4341. 
[47] V.V. Rostovtsev, L.G. Green, V.V. Fokin, K.B. Sharpless, A stepwise huisgen cycloaddition 
process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes, Angew. Chem., 
Int. Ed. 41 (2002) 2596–2599. 
[48] P.K. Avti, D. Maysinger, A. Kakkar, Alkyne-Azide “Click” Chemistry in Designing Nanocarriers 
for Applications in Biology, Molecules 18 (2013) 9531–9549. 
[49] G.L. Ellman, K.D. Courtney, V. Andres, R.M. Featherstone, A new and rapid colorimetric 
determination of acetylcholinesterase activity, Biochem. Pharmacol. 7 (1961) 88–95. 
[50] B.R. Brooks, R.E. Bruccoleri, B.D. Olafson, D.J. States, S. Swaminathan, M. Karplus, 
CHARMM: A program for macromolecular energy, minimization, and dynamics calculations, J. Comp. 
Chem. 4 (1983) 187–217. 
[51] F.A. Momany, R. Rone, Validation of the general purpose QUANTA 3.2/CHARMm force field, J. 
Comp. Chem. 13 (1992) 888–900. 
[52] G. Kryger,  M. Harel,  K. Giles,  L. Toker,  B. Velan,  A. Lazar,  C. Kronman,  D. Barak,  N. Ariel,  
A. Shafferman,  I. Silman,  J.L. Sussman. Structures of recombinant native and E202Q mutant human 
acetylcholinesterase complexed with the snake-venom toxin fasciculin-II,  Acta Crystallogr., Sect. D 56 
(2000) 1385–1394 
[53] M.N. Ngamelue,  K. Homma, O. Lockridge, O.A. Asojo, Crystallization and X-ray structure of 
full-length recombinant human butyrylcholinesterase, Acta Crystallogr., Sect. F 63 (2007) 723–727. 
[54] M. Feig, C.L. Brooks III, Recent advances in the development and application of implicit solvent 
models in biomolecule simulations, Curr. Opin. Struct. Biol. 14 (2004) 217–224. 
[55] M. Nina, D. Beglov, B. Roux, Atomic Born radii for continuum electrostatic calculations based on 
molecular dynamics free energy simulations, J. Phys. Chem. B. 101 (1997) 5239–5248. 
[56] F. Nachon, E. Carletti, C. Ronco, M. Trovaslet, Y. Nicolet, L. Jean, P.-Y. Renard, Crystal 
structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for 
anti-Alzheimer’s drugs targeting acetyl- and butyryl-cholinesterase, Biochem. J. 453 (2013) 393–399. 
[57] H.M. Greenblatt, G. Kryger, T. Lewis, I. Silman, J.L. Sussman, Structure of acetylcholinesterase 
complexed with (–)-galanthamine at 2.3 Å resolution, FEBS Lett. 463 (1999) 321–326. 
[58] J. Cheung, M.J. Rudolph, F. Burshteyn, M.S. Cassidy, E.N. Gary, J. Love, M.C. Franklin, J.J. 
Height, Structures of human acetylcholinesterase in complex with pharmacologically important 
ligands, J. Med. Chem. 55 (2012) 10282–10286. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
16 
 
[59] M. Harel, I. Schalk, L. Ehret-Sabatier, F. Bouet, M. Goeldner, C. Hirth, P.H. Axelsen, I. Silman, 
J.L. Sussman, Quaternary ligand binding to aromatic residues in the active-site gorge of 
acetylcholinesterase, Proc. Natl. Acad. Sci USA 90 (1993) 9031–9035. 
[60] F. Ekström, Y.-P. Pang, M. Boman, E. Artursson, C. Akfur, S. Börjegren, Crystal structures of 
acetylcholinesterase in complex with HI-6, Ortho-7 and obidoxime: Structural basis for differences in 
the ability to reactivate tabun conjugates, Biochem. Pharmacol. 72 (2006) 597–607. 
[61] L.W. Harris, W.C. Heyl, D.L. Stitcher, C.A. Broomfield, Effects of 1.1´-oxydimethylene bis-(4-
tert-butylpyridinium chloride) (SAD-128) and decamethonium on reactivation of soman and sarin-
inhibited cholinesterase by oximes, Biochem. Pharmacol. 27 (1978) 757–761. 
[62] J. Bajgar, Prophylaxis against organophosphorus poisoning, J. Med. Che. Def. 1 (2004) 1–16. 
[63] E. Reiner, Inhibition of acetylcholinesterase by 4,4´-bipyridine and its effect upon phosphylation 
of the enzyme, Croat. Chem. Acta 59 (1986) 925–931.  
[64] G. Lallement, V. Baille, D. Baubichon, P. Carpentier, J.M. Collombet, P. Filliat, A. Foquin, E. 
Four, C. Masqueliez, G. Testylier, L. Tonduli, F. Dorandeu, Review of the value of huperzine as 
pretreatment of organophosphate poisoning, Neurotoxicology 23 (2002) 1–5. 
[65] S. Eckert, P. Eyer, H. Muckter, F. Worek, Kinetic analysis of the protection afforded by reversible 
inhibitors against irreversible inhibition of acetylcholinesterase by highly toxic organophosphorus 
compounds, Biochem. Pharmacol. 72 (2006) 344–357. 
[66] M.A. Dunn, B.E. Hackley, F.R. Sidell, Pretreatment for nerve agent exposure, in: F.R. Sidell, E.T. 
Takafuji, D.R. Franz (Eds.), Medical Aspects of Chemical Biological Warfare. Walter Reed Army 
Medical Center, Washington, 1997, pp. 181–196.  
[67] D.E. Lenz, C.A. Broomfield, D.M. Maxwell, D.M. Cerasoli,. Nerve agent bioscavengers: 
protection against high- and low-dose organophosphorus exposure, in: S.M. Somani, J.A. Romano Jr. 
(Eds.), Chemical Warfare Agents: Toxicity at Low Levels. CRS Press LLC, Boca Raton, Florida, 2001, 
pp. 215–243. 
[68] L. Raveh, E. Grauer, J. Grunwald, E. Cohen, Y. Ashani, The stoichiometry of protection against 
soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase, Toxicol. Appl. 
Pharmacol. 145 (1997) 43−53. 
[69] P. Masson, F. Nachon, C. A. Broomfield, D. E. Lenz, L. Verdier, L.M. Schopfer, O. Lockridge, A 
collaborative endeavor to design cholinesterase-based catalytic scavengers against toxic 
organophosphorus esters. Chem. Biol. Interact. 175 (2008) 273−280. 
[70] A. Lucić Vrdoljak, M. Čalić, B. Radić, S. Berend, D. Jun, K. Kuča, Z. Kovarik, Pretreatment with 
pyridinium oximes improves antidotal therapy against tabun poisoning, Toxicology 228 (2006) 41-50.  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
17 
 
 
Table 1 
Reversible inhibition of human recombinant acetylcholinesterase (AChE) and horse serum butyrylcholinesterase (BChE) by 
N-substituted 2-hydroxyiminoacetamides 1-4. 
N-substituted 2-
hydroxyiminoacetamide 
[ATCh] / 
mmol/L 
[N-substituted 2- 
hydroxyiminoacetamide] / 
μmol/L 
Ki / μmol/L α 
AChE 
1 0.1-0.6 500-1500 1187 ± 248 2.5 ± 1.0 
2 0.1-0.6 30-150
a
 358 ± 197 0.9 ± 0.7 
3 0.1-0.8 15-80 49 ± 22 2.9 ± 1.5 
4 0.1-0.8 50-200 135 ± 26 4.8 ± 1.3 
BChE 
1 0.1-0.8 50-200 132 ± 14 6.3 ± 2.2 
2 0.1-0.8 15-75 42 ± 4 15 ± 10 
3 0.1-0.8 0.1-0.4 0.33 ± 0.03 6.0 ± 1.7 
4 0.1-0.8 20-100 30 ± 3 5.7 ± 1.8 
a
Due to the low solubility of 2 in 0.1 M sodium phosphate buffer, pH  7.4, the constant could not be evaluated at higher 
concentration of 2. 
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Table 2 
List of N-substituted 2-hydroxyiminoacetamide–enzyme interactions. 
Enzyme N-substituted 2-
hydroxyiminoacetamide 
Interactions
a
 
AChE   
 
1 D) Tyr133  
A) Ser203, His447 
π-π) Trp86 
 
2 D) Tyr124, Ser203, Tyr337 
A)  none 
π-π) Trp86 
 
3 D) none 
A) Glu202 
π-π) Tyr124, Trp286, Phe297 (π-sigma), Tyr341 
 
4 D) Ser203, Phe295 
A) Glu202 
π-π) Trp86, Tyr341 (π-sigma) 
BChE   
 
1 D) Ser198, 
A) Ser198, 
π-π) Trp82, 
 
2 D) Ser198 
A) Leu286 
π-π) Trp82, Phe329 
 
3 D) Gly116, Gly117 
A) Ser198, Pro285 
π-π) Trp82, His438 
 
4 D) Thr120 
A) Trp82 
π-π) Trp82, Tyr332 
a 
D) H-bond donor; A) H-bond acceptor; π-π interactions. 
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Fig. 1. Structures of cholinesterase inhibitors, and reactivators of organophosphorus nerve agent-
inhibited cholinesterases. 
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Fig. 2. Chemical structures of synthesized N-substituted 2-hydroxyiminoacetamides. 
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Fig. 3. Representative plot of AChE activity and the effect of substrate concentration on AChE activity 
in the presence and absence of N-substituted 2-hydroxyiminoacetamide 3. To limit the influence of 
DMSO on the degree of enzyme inhibition the final content of DMSO was held constant at 0.1 %. 
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Fig. 4. The stereo view of docked conformation of the N-substituted 2-hydroxyiminoacetamides 1–4 (A–D, respectively) in 
the active site of the AChE. Non-covalent interactions are shown as green dashed lines (H-bonds) and orange lines (π 
interactions).  
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Fig. 5. The stereo view of docked conformation of the N-substituted 2-hydroxyiminoacetamides 1–4 (A–D) in the active site 
of the BChE. Non-covalent interactions are shown as green dashed lines (H-bonds) and orange lines (π interactions). 
